COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00629733
Recruitment Status : Completed
First Posted : March 6, 2008
Last Update Posted : June 8, 2011
Information provided by:
Rovi Pharmaceuticals Laboratories

Brief Summary:
Clinical trial to evaluate the tolerability and pharmacokinetics of a new ultra low molecular weight heparin (RO-14) administered subcutaneously increasing single-doses to healthy male volunteers

Condition or disease Intervention/treatment Phase
Healthy Drug: RO-14 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : December 2007
Actual Primary Completion Date : December 2007
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners

Arm Intervention/treatment
Experimental: Ro-14 Drug: RO-14

Primary Outcome Measures :
  1. Main objective : To evaluate safety and tolerability of increasing single-doses to healthy male volunteers [ Time Frame: safety parameters ]

Secondary Outcome Measures :
  1. Secondary objectives : To evaluate pharmacokinetics profiles of each of single-doses. [ Time Frame: anti-Xa activity ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy volunteers: male subjects aged between 18 and 45 years
  2. Body weight: 65-75 Kg
  3. Not meaningful abnormalities in physical examination and in clinical history
  4. Without evidence of significant organic or psychiatric illness
  5. Hemogram, biochemistry and coagulation in normal values established in the reference range of the local hospital laboratory
  6. Vital signs (blood pressure, heart beat rate and body temperature) and EKG within normal range
  7. Healthy volunteers who are not participating in another clinical trial or have not done so in the past 2 months
  8. Not give blood in the last 4 weeks.
  9. Healthy male volunteers who have not received heparin in the past
  10. Healthy male volunteers who have accepted to participate in the study and have signed the written informed consent

Exclusion Criteria:

  1. Previous history of alcoholism, drug dependency, drug abuse or habitual psychoactive drugs consumption
  2. Important consumption of exciting drinks: alcohol consumption > 30 g/day; coffee, tea, cola > 5 /day
  3. Allergy, idiosyncrasy or hypersensitivity to medicines
  4. Healthy volunteers who are receiving another medication in the past 15 days
  5. Positive serology of hepatitis B, C or HIV
  6. Cardiovascular, respiratory, renal, hepatic, endocrine, gastrointestinal, hematologic, psychiatric, neurological and others events
  7. Mayor Surgery in the last 6 months
  8. Smoking > 10 cigarettes / day
  9. Ethanol, cannabis, cocaine, amphetamine, benzodiazepine or opiate in urine
  10. Healthy volunteers with a familiar history evident hemorrhagic episodes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00629733

Layout table for location information
Hospital Santa Creu i Sant Pau
Barcelona, Spain
Sponsors and Collaborators
Rovi Pharmaceuticals Laboratories
Layout table for investigator information
Principal Investigator: Dr Manuel Barbanoj Hospital Santa Creu i Sant Pau
Layout table for additonal information
Responsible Party: Dr. Barbanoj, Hospital Santa Creu i Sant Pau Identifier: NCT00629733    
Other Study ID Numbers: ROV-RO14-2006-01
First Posted: March 6, 2008    Key Record Dates
Last Update Posted: June 8, 2011
Last Verified: June 2011
Keywords provided by Rovi Pharmaceuticals Laboratories:
ultra low molecular weight heparin